Profiles

Keywords
Last Name
Institution

Timothy Kuzel

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 35411582100.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? ACG Case Rep J. 2017; 4:e112. PMID: 29043290.
      View in: PubMed
    2. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 05; 390(10094):555-566. PMID: 28600132.
      View in: PubMed
    3. Schwartz C, Pfanzelter N, Kuzel TM. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. Clin Genitourin Cancer. 2017 Oct; 15(5):e903-e906. PMID: 28624319.
      View in: PubMed
    4. Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697. PMID: 28334439.
      View in: PubMed
    5. Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang L, Zhang Z, Zhang Y, Fang D, Kuzel TM, Zhang B. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol. 2017 Feb 01; 198(3):1365-1375. PMID: 28011934.
      View in: PubMed
    6. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct; 14(10):1213-1224. PMID: 27697976.
      View in: PubMed
    7. Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, Fang D, Zhang Y, Kuzel TM, Zhang B. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016 Sep 20; 7(38):61069-61080. PMID: 27517629.
      View in: PubMed
    8. George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 Sep 01; 2(9):1179-86. PMID: 27243803.
      View in: PubMed
    9. Minami CA, Wayne JD, Yang AD, Martini MC, Gerami P, Chandra S, Kuzel TM, Winchester DP, Palis BE, Bilimoria KY. National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures. Ann Surg Oncol. 2016 Oct; 23(11):3548-3557. PMID: 27278202.
      View in: PubMed
    10. Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. JAMA Oncol. 2016 Jun 01; 2(6):790-3. PMID: 27054291.
      View in: PubMed
    11. Olson D, Bhalla S, Yang X, Martone B, Kuzel TM. Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review. Clin Genitourin Cancer. 2016 08; 14(4):e445-8. PMID: 27079472.
      View in: PubMed
    12. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090; PMCID: PMC4878938 [Available on 05/14/17].
    13. Rimar KJ, Meeks JJ, Kuzel TM. Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):e431-4. PMID: 27021586.
      View in: PubMed
    14. Ye C, Geng Z, Dominguez D, Chen S, Fan J, Qin L, Long A, Zhang Y, Kuzel TM, Zhang B. Targeting Ornithine Decarboxylase by a-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol. 2016 Jan 15; 196(2):915-23. PMID: 26663722; PMCID: PMC4707077 [Available on 01/15/17].
    15. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015 Nov 10; 33(32):3766-73. PMID: 26438120; PMCID: PMC4979132.
    16. Gentile MS, Martinez-Escala ME, Thomas TO, Guitart J, Rosen S, Kuzel T, Mittal BB. Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders. Biomed Res Int. 2015; 2015:629587. PMID: 26504818; PMCID: PMC4609348.
    17. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99. PMID: 26085393.
      View in: PubMed
    18. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9. PMID: 25691606.
      View in: PubMed
    19. Kaiser K, Beaumont JL, Webster K, Yount SE, Wagner LI, Kuzel TM, Cella D. Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale. Cancer Med. 2015 May; 4(5):690-8. PMID: 25619758; PMCID: PMC4430262.
    20. Chen S, Zhang Y, Kuzel TM, Zhang B. Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs. Cancer Cell Microenviron. 2015; 2(1). PMID: 26005707.
      View in: PubMed
    21. Chen S, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang D, Kuzel TM, Zhang B. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 2015 Feb 01; 75(3):519-31. PMID: 25502838; PMCID: PMC4315710.
    22. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 01; 33(13):1430-7. PMID: 25452452; PMCID: PMC4806782.
    23. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015 Feb; 41(2):170-8. PMID: 25498841.
      View in: PubMed
    24. Pettijohn E, Martone B, Rademaker A, Kuzel T. A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma. J Pers Med. 2014 Oct 17; 4(4):448-58. PMID: 25563456; PMCID: PMC4282882.
    25. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5. PMID: 25075565; PMCID: PMC4127096.
    26. Memon K, Kuzel TM, Vouche M, Atassi R, Lewandowski RJ, Salem R. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience. Melanoma Res. 2014 Jun; 24(3):244-51. PMID: 24638152.
      View in: PubMed
    27. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. PMID: 24812137.
      View in: PubMed
    28. Guitart J, Deonizio J, Bloom T, Martinez-Escala ME, Kuzel TM, Gerami P, Kwasny M, Rosen ST. High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas. JAMA Dermatol. 2014 Apr; 150(4):412-8. PMID: 24500411.
      View in: PubMed
    29. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82. PMID: 24586079.
      View in: PubMed
    30. Qin L, Thompson LF, Kuzel TM, Zhang B. Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis. Immunotherapy. 2014; 6(1):19-21. PMID: 24341879; PMCID: PMC3968679.
    31. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014 Feb 20; 123(8):1159-66. PMID: 24335103.
      View in: PubMed
    32. Gunawardane ND, Vaghani SP, Kuzel TM, Cotliar JA. Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2. J Am Acad Dermatol. 2013 Oct; 69(4):e183-4. PMID: 24034391.
      View in: PubMed
    33. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615. PMID: 23667209; PMCID: PMC4042432.
    34. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75. PMID: 23584347.
      View in: PubMed
    35. Wu L, Runkle C, Jin HJ, Yu J, Li J, Yang X, Kuzel T, Lee C, Yu J. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene. 2014 Jan 23; 33(4):504-13. PMID: 23318417; PMCID: PMC3796014.
    36. Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed. 2012 Oct; 28(5):250-7. PMID: 22971190.
      View in: PubMed
    37. Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, Hayes JP, Kuzel TM, Mittal BB. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):747-53. PMID: 22818412.
      View in: PubMed
    38. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr; 10(4):502-35. PMID: 22491049.
      View in: PubMed
    39. Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol. 2012 Mar; 13(1):102-21. PMID: 22311555.
      View in: PubMed
    40. Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, Kuzel TM, Zhu LJ, Yang XJ, Javonovic B, Guo Y, Lonning S, Harper J, Teicher BA, Brendler C, Yu N, Catalona WJ, Lee C. TGF-ß regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS One. 2011; 6(9):e25168. PMID: 21980391; PMCID: PMC3184137.
    41. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 01; 9(9):960-77. PMID: 21917622.
      View in: PubMed
    42. Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res. 2011 Sep 01; 17(17):5748-54. PMID: 21747120; PMCID: PMC3725971.
    43. Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011 Aug; 52(8):1474-80. PMID: 21649541.
      View in: PubMed
    44. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27. PMID: 21631324; PMCID: PMC3517182.
    45. Matkowskyj KA, Hosseini A, Linn JG, Yang GY, Kuzel TM, Wayne JD. Merkel cell carcinoma metastatic to the small bowel mesentery. Rare Tumors. 2011 Mar 30; 3(1):e2. PMID: 21464875; PMCID: PMC3070447.
    46. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010 Dec; 63(6):975-83. PMID: 20888065.
      View in: PubMed
    47. Parajuli R, Altman J, Kuzel T, Perdekamp M, Tallman M. Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association? Am J Hematol. 2010 Oct; 85(10):829. PMID: 20721888.
      View in: PubMed
    48. Atchison E, Eklund J, Martone B, Wang L, Gidron A, Macvicar G, Rademaker A, Goolsby C, Marszalek L, Kozlowski J, Smith N, Kuzel TM. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC). J Immunother. 2010 Sep; 33(7):716-22. PMID: 20664355.
      View in: PubMed
    49. St Pierre SA, Rommel J, Ciurea A, Fife D, Yoo SS, Martini M, Kuzel TM, Wayne J, Rademaker A, West DP, Alam M. In situ photoimmunotherapy: a surgery- and limb-sparing approach to the treatment of cutaneous metastases in advanced melanoma. Arch Dermatol. 2010 Aug; 146(8):831-4. PMID: 20713811.
      View in: PubMed
    50. Gerami P, Wickless SC, Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol. 2010 Jul; 63(1):142-5. PMID: 20462658.
      View in: PubMed
    51. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009 Dec; 50(12):1969-76. PMID: 19860617.
      View in: PubMed
    52. Liu SW, Guitart JG, Kuzel TM, Gandhi M, Lacouture M. Effect of sunitinib on renal cell carcinoma cutaneous metastasis. Int J Dermatol. 2009 Nov; 48(11):1269-70. PMID: 20064194.
      View in: PubMed
    53. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer. 2009 Oct; 7(3):E58-65. PMID: 19815483.
      View in: PubMed
    54. Gandhi M, Kuzel T, Lacouture M. Eosinophilic rash secondary to temsirolimus. Clin Genitourin Cancer. 2009 Aug; 7(2):E34-6. PMID: 19692320.
      View in: PubMed
    55. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405. PMID: 19636013; PMCID: PMC2744277.
    56. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):672-93. PMID: 19555582.
      View in: PubMed
    57. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):618-30. PMID: 19555584.
      View in: PubMed
    58. Rao D, Butt Z, Rosenbloom S, Robinson D, Von Roenn J, Kuzel TM, Cella D. A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage. 2009 Aug; 38(2):291-8. PMID: 19356897; PMCID: PMC2901424.
    59. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39. PMID: 19176203.
      View in: PubMed
    60. Gerami P, Guitart J, Martini M, Wayne JD, Kuzel T. Cyclin D1 homogeneous staining regions by fluorescent in situ hybridization: a possible indicator of aggressive behavior in melanomas. Arch Dermatol. 2008 Sep; 144(9):1235-6. PMID: 18794480.
      View in: PubMed
    61. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008 Jun; 144(6):738-46. PMID: 18559762.
      View in: PubMed
    62. Gerami P, Wickless SC, Rosen S, Kuzel TM, Ciurea A, Havey J, Guitart J. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol. 2008 Aug; 59(2):245-54. PMID: 18486274.
      View in: PubMed
    63. Meeks JJ, Kasper KA, Yang X, Kuzel TM, Smith ND. Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor. Urology. 2009 Feb; 73(2):444.e11-2. PMID: 18384863.
      View in: PubMed
    64. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 3:S1-14. PMID: 18377852.
      View in: PubMed
    65. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24. PMID: 18314434.
      View in: PubMed
    66. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008 Jun; 16(6):557-66. PMID: 18274784.
      View in: PubMed
    67. Gerami P, Guitart J, Rosen S, Kuzel TM. Interleukins in the treatment of mycosis fungoides. G Ital Dermatol Venereol. 2008 Feb; 143(1):55-8. PMID: 18833051.
      View in: PubMed
    68. Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol. 2008 Jan; 129(1):146-56. PMID: 18089499.
      View in: PubMed
    69. Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma. 2007 Dec; 48(12):2397-402. PMID: 17943599.
      View in: PubMed
    70. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20; 25(21):3109-15. PMID: 17577020.
      View in: PubMed
    71. Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007 May 28; 167(10):1041-9. PMID: 17533207.
      View in: PubMed
    72. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01; 109(9):1799-803. PMID: 17366595.
      View in: PubMed
    73. Querfeld C, Kuzel TM, Guitart J, Rosen ST. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology (Williston Park). 2007 May; 21(6):689-96; discussion 699-700,. PMID: 17564326.
      View in: PubMed
    74. Lai SE, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. J Clin Oncol. 2007 Jan 20; 25(3):341-3. PMID: 17235051.
      View in: PubMed
    75. Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, Kuzel TM. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2007 Apr; 56(4):580-3. PMID: 17367611.
      View in: PubMed
    76. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1072-81. PMID: 17112454.
      View in: PubMed
    77. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):984-1014. PMID: 17112448.
      View in: PubMed
    78. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1038-58. PMID: 17112452.
      View in: PubMed
    79. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec; 135(5):642-50. PMID: 17054431.
      View in: PubMed
    80. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol. 2006 Nov; 55(5):807-13. PMID: 17052486.
      View in: PubMed
    81. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604. PMID: 16959316.
      View in: PubMed
    82. Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther. 2006 Jul; 5(7):1733-43. PMID: 16891459.
      View in: PubMed
    83. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother. 2006 May; 7(7):907-15. PMID: 16634713.
      View in: PubMed
    84. Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer. 2006 May 01; 106(9):2051-7. PMID: 16568459.
      View in: PubMed
    85. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, Krett NL, Rosen ST. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006 Jul; 126(7):1641-7. PMID: 16645590.
      View in: PubMed
    86. Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate. 2006 Feb 15; 66(3):235-47. PMID: 16173028.
      View in: PubMed
    87. Soff GA, Wang H, Cundiff DL, Jiang K, Martone B, Rademaker AW, Doll JA, Kuzel TM. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 2005 Sep 01; 11(17):6218-25. PMID: 16144924.
      View in: PubMed
    88. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7. PMID: 16099877; PMCID: PMC1895064.
    89. Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol. 2005 Jul; 12(4):273-8. PMID: 15928483.
      View in: PubMed
    90. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005 May 04; 293(17):2131-40. PMID: 15870417.
      View in: PubMed
    91. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005 Mar 01; 65(5):1761-9. PMID: 15753372.
      View in: PubMed
    92. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH, Prinz BM, Guitart J. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005 Mar; 141(3):305-11. PMID: 15781671.
      View in: PubMed
    93. Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther. 2005 Feb; 5(1):33-8. PMID: 15757436.
      View in: PubMed
    94. Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Netw. 2005 Jan; 3(1):52-76. PMID: 19813323.
      View in: PubMed
    95. Parmar S, Rademaker AW, Fung BB, Kozlowski JM, Kuzel TM. Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience. Med Oncol. 2005; 22(4):399-405. PMID: 16260858.
      View in: PubMed
    96. Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jan; 3(1):4-5, 19-34. PMID: 19813320.
      View in: PubMed
    97. Eklund JW, Kuzel TM. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res. 2005; 126:263-87. PMID: 16209070.
      View in: PubMed
    98. Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. Kidney cancer. Clinical practice guidelines. J Natl Compr Canc Netw. 2005 Jan; 3(1):84-93. PMID: 19813325.
      View in: PubMed
    99. Querfeld C, Guitart J, Kuzel TM, Rosen S. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept. Arch Dermatol. 2004 Dec; 140(12):1539-40. PMID: 15611443.
      View in: PubMed
    100. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol. 2004 Nov; 16(6):542-6. PMID: 15627015.
      View in: PubMed
    101. Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004 Nov; 45(11):2269-73. PMID: 15512816.
      View in: PubMed
    102. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 Sep 30; 351(14):1403-8. PMID: 15459301.
      View in: PubMed
    103. Pichardo DA, Querfeld C, Guitart J, Kuzel TM, Rosen ST. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk Lymphoma. 2004 Sep; 45(9):1755-65. PMID: 15223633.
      View in: PubMed
    104. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. PMID: 15464919.
      View in: PubMed
    105. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004 Sep 01; 101(5):957-62. PMID: 15329903.
      View in: PubMed
    106. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004 Jul; 51(1):25-32. PMID: 15243520.
      View in: PubMed
    107. Elstein AS, Chapman GB, Chmiel JS, Knight SJ, Chan C, Nadler RB, Kuzel TM, Siston AK, Bennett CL. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115-25. PMID: 15117386.
      View in: PubMed
    108. Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003 Dec; 17(6):1475-83, xi. PMID: 14710898.
      View in: PubMed
    109. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am. 2003 Dec; 17(6):1435-48, ix. PMID: 14710894.
      View in: PubMed
    110. Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003 Dec; 17(6):1459-66, x. PMID: 14710896.
      View in: PubMed
    111. Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol. 2003 Oct; 31(10):903-10. PMID: 14550806.
      View in: PubMed
    112. Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches. Semin Cutan Med Surg. 2003 Sep; 22(3):150-61. PMID: 14649582.
      View in: PubMed
    113. Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev. 2003 Sep; 17(3):131-42. PMID: 12818223.
      View in: PubMed
    114. Wu JJ, Guitart J, Tucker RM, Kuzel TM, Rosen ST. Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol. 2003 Jun; 42(6):464-5. PMID: 12786875.
      View in: PubMed
    115. Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology. 2003 Jan; 61(1):172-8. PMID: 12559291.
      View in: PubMed
    116. Kuzel TM. Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome. Dermatol Ther. 2003; 16(4):355-61. PMID: 14686979.
      View in: PubMed
    117. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol. 2002 Oct; 138(10):1359-65. PMID: 12374543.
      View in: PubMed
    118. Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, Viola M, Sosman JA. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol. 2002 Apr; 13(4):606-13. PMID: 12056712.
      View in: PubMed
    119. Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002 Apr 01; 20(7):1859-63. PMID: 11919245.
      View in: PubMed
    120. Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002 Mar; 2(1):19-36. PMID: 12188918.
      View in: PubMed
    121. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma. 2002 Mar; 2(4):222-8. PMID: 11970761.
      View in: PubMed
    122. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002 Mar; 138(3):325-32. PMID: 11902983.
      View in: PubMed
    123. Kuzel TM, Kies MS, Wu N, Hsieh YC, Rademaker AW. Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer. Cancer Invest. 2002; 20(5-6):634-43. PMID: 12197218.
      View in: PubMed
    124. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001 Sep; 941:177-84. PMID: 11594571.
      View in: PubMed
    125. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia/lymphoma. Curr Treat Options Oncol. 2001 Aug; 2(4):291-300. PMID: 12057109.
      View in: PubMed
    126. Duvic M, Olsen EA, Omura GA, Maize JC, Vonderheid EC, Elmets CA, Shupack JL, Demierre MF, Kuzel TM, Sanders DY. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001 Jun; 44(6):940-7. PMID: 11369904.
      View in: PubMed
    127. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001 Mar; 1(4):298-302. PMID: 11707845.
      View in: PubMed
    128. Knight SJ, Chmiel JS, Sharp LK, Kuzel T, Nadler RB, Fine R, Moran EM, Sharifi R, Bennett CL. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology. 2001 Feb; 57(2):275-80. PMID: 11182336.
      View in: PubMed
    129. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15; 19(2):376-88. PMID: 11208829.
      View in: PubMed
    130. Kim SP, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L, Kuzel TM, Nadler RB, Bennett CL. Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. Cancer Invest. 2001; 19(7):684-91. PMID: 11577809.
      View in: PubMed
    131. Siegel R, Gartenhaus R, Kuzel T. HTLV-I associated leukemia/lymphoma: epidemiology, biology, and treatment. Cancer Treat Res. 2001; 104:75-88. PMID: 11191136.
      View in: PubMed
    132. Argiris A, Heald P, Kuzel T, Foss FM, DiStasio S, Cooper DL, Arbuck S, Murren JR. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Invest New Drugs. 2001; 19(4):321-6. PMID: 11561692.
      View in: PubMed
    133. Kuzel TM. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. Clin Lymphoma. 2000 Nov; 1 Suppl 1:S33-6. PMID: 11707861.
      View in: PubMed
    134. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000 Aug; 18(15):2908-25. PMID: 10920140.
      View in: PubMed
    135. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7. PMID: 10784633.
      View in: PubMed
    136. Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, Guitart J. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol. 2000 May; 18(10):2152-68. PMID: 10811681.
      View in: PubMed
    137. Siegel RS, Kuzel TM. Cutaneous T-cell lymphoma/leukemia. Curr Treat Options Oncol. 2000 Apr; 1(1):43-50. PMID: 12057060.
      View in: PubMed
    138. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24. PMID: 10717612.
      View in: PubMed
    139. Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, Kuzel TM. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant. 2000 Jan; 25(1):111-3. PMID: 10654025.
      View in: PubMed
    140. Guitart J, Variakojis D, Kuzel T, Rosen S. Cutaneous CD8 T cell infiltrates in advanced HIV infection. J Am Acad Dermatol. 1999 Nov; 41(5 Pt 1):722-7. PMID: 10534634.
      View in: PubMed
    141. Sharp LK, Knight SJ, Nadler R, Albers M, Moran E, Kuzel T, Sharifi R, Bennett C. Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res. 1999 Aug; 8(5):461-70. PMID: 10474287.
      View in: PubMed
    142. Dolan ME, McRae BL, Ferries-Rowe E, Belanich M, van Seventer GA, Guitart J, Pezen D, Kuzel TM, Yarosh DB. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res. 1999 Aug; 5(8):2059-64. PMID: 10473086.
      View in: PubMed
    143. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999 Aug; 17(8):2541-5. PMID: 10561320.
      View in: PubMed
    144. Kim SP, Bennett CL, Chan C, Chmiel J, Falcone D, Knight SJ, Kuzel T, Davis TC, Elstein AS, Moran E, Robertson CN, Smith JS. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Williston Park). 1999 Jun; 13(6):823-32; discussion 835-8. PMID: 10378220.
      View in: PubMed
    145. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res. 1999 May; 8(3):171-80. PMID: 10472149.
      View in: PubMed
    146. Burt RK, Kuzel TM, Fishman M, Brush M, Villa M, Welles C, Rosen S, Traynor AE. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells. Bone Marrow Transplant. 1999 Feb; 23(4):381-6. PMID: 10100582.
      View in: PubMed
    147. Foss FM, Kuzel TM. Novel treatment approaches for cutaneous T-cell lymphoma. Cancer Treat Res. 1999; 99:227-40. PMID: 9891869.
      View in: PubMed
    148. Engel JD, Kuzel TM, Moceanu MC, Oefelein MG, Schaeffer AJ. Angiosarcoma of the bladder: a review. Urology. 1998 Nov; 52(5):778-84. PMID: 9801098.
      View in: PubMed
    149. Knight SJ, Chmiel JS, Kuzel T, Sharp L, Albers M, Fine R, Moran EM, Nadler RB, Sharifi R, Bennett CL. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol. 1998 Nov; 160(5):1765-9. PMID: 9783948.
      View in: PubMed
    150. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998 Sep; 16(9):3101-4. PMID: 9738581.
      View in: PubMed
    151. Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73. PMID: 9674399.
      View in: PubMed
    152. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A, Bennett CL. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998 Jul-Sep; 18(3):278-86. PMID: 9679992.
      View in: PubMed
    153. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am. 1998 May-Jun; 4(3):162-7. PMID: 9612597.
      View in: PubMed
    154. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998 May; 16(5):1820-5. PMID: 9586896.
      View in: PubMed
    155. Salard D, Kuzel TM, Samuelson E, Rosen S, Bakouche O. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes. J Clin Immunol. 1998 May; 18(3):223-34. PMID: 9624582.
      View in: PubMed
    156. Kong LR, Huang CF, Hakimian D, Variakojis D, Klein L, Kuzel TM, Gordon LI, Zanzig C, Wollins E, Tallman MS. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Cancer. 1998 Mar 01; 82(5):957-64. PMID: 9486587.
      View in: PubMed
    157. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405. PMID: 9427692.
      View in: PubMed
    158. Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs. 1998; 16(2):191-5. PMID: 9848585.
      View in: PubMed
    159. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov; 15(11):3394-8. PMID: 9363871.
      View in: PubMed
    160. Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3. PMID: 9167747.
      View in: PubMed
    161. Kong LR, Samuelson E, Rosen ST, Roenigk HH, Tallman MS, Rademaker AW, Kuzel TM. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma. 1997 Jun; 26(1-2):89-97. PMID: 9250792.
      View in: PubMed
    162. Thangavelu M, Finn WG, Yelavarthi KK, Roenigk HH, Samuelson E, Peterson L, Kuzel TM, Rosen ST. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood. 1997 May 01; 89(9):3371-7. PMID: 9129044.
      View in: PubMed
    163. Gonzalez CM, Kuzel T, Carter MA. Metastatic adenocarcinoma of the prostate to the orbit as a presenting symptom. J Urol. 1997 Feb; 157(2):625. PMID: 8996376.
      View in: PubMed
    164. Bennett CL, Chapman G, Elstein AS, Knight SJ, Nadler RB, Sharifi R, Kuzel T. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol. 1997; 32 Suppl 3:86-8. PMID: 9267792.
      View in: PubMed
    165. Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Metastatic bladder cancer: advances in treatment. Eur J Cancer. 1997 Jan; 33 Suppl 1:S23-6. PMID: 9166096.
      View in: PubMed
    166. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6. PMID: 9166099.
      View in: PubMed
    167. Ullman M, Metzger CK, Kuzel T, Bennett CL. Performance measurement in prostate cancer care: beyond report cards. Urology. 1996 Mar; 47(3):356-65. PMID: 8633402.
      View in: PubMed
    168. Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, Roenigk H, Rosen S. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996 Feb; 34(2 Pt 1):304-6. PMID: 8642101.
      View in: PubMed
    169. Kuzel TM, Hurria A, Samuelson E, Tallman MS, Roenigk HH, Rademaker AW, Rosen ST. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood. 1996 Feb 01; 87(3):906-11. PMID: 8562961.
      View in: PubMed
    170. Foss FM, Kuzel TM. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct; 9(5):1127-37. PMID: 8522489.
      View in: PubMed
    171. Herrmann JJ, Roenigk HH, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, Rosen ST. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995 Aug; 33(2 Pt 1):234-42. PMID: 7622650.
      View in: PubMed
    172. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15; 75(8):2169-73. PMID: 7697608.
      View in: PubMed
    173. Kuzel TM, Roenigk HH, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, Rosen ST. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol. 1995 Jan; 13(1):257-63. PMID: 7799028.
      View in: PubMed
    174. Lyster MT, Kies MS, Kuzel TM. Neurologic complications of patients with small cell prostate carcinoma. Report of two cases. Cancer. 1994 Dec 15; 74(12):3159-63. PMID: 7982180.
      View in: PubMed
    175. Kuzel TM, Rosen ST. Antibodies in the treatment of human cancer. Curr Opin Oncol. 1994 Nov; 6(6):622-6. PMID: 7827176.
      View in: PubMed
    176. Herrmann JJ, Kuzel TM, Rosen ST, Roenigk HH. Proceedings of the Second International Symposium on Cutaneous T-cell Lymphoma. Chicago, Illinois, Oct. 13-17, 1993. J Am Acad Dermatol. 1994 Nov; 31(5 Pt 1):819-22. PMID: 7523465.
      View in: PubMed
    177. Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994 Apr; 12(4):788-92. PMID: 7908690.
      View in: PubMed
    178. Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. Nephron. 1994; 67(1):94-100. PMID: 7914355.
      View in: PubMed
    179. Kuzel TM, Rosen ST, Gordon LI, Winter J, Samuelson E, Kaul K, Roenigk HH, Nylen P, Woodworth T. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma. 1993 Nov; 11(5-6):369-77. PMID: 8124209.
      View in: PubMed
    180. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vogelzang NJ, Blough R, Benson AB. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993 Sep 15; 72(6):1965-8. PMID: 8364875.
      View in: PubMed
    181. Springer EA, Kuzel TM, Variakojis D, Kaul K, Rosen ST, Roenigk HH. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. J Am Acad Dermatol. 1993 Jul; 29(1):42-6. PMID: 7686188.
      View in: PubMed
    182. Kuzel T, Rosen ST, Zimmer AM, Silverstein EA, Spies S, Saletan SL, Norvitch ME, Birkhofer M, Shochat D, LoBuglio AF, et al. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. Cancer Biother. 1993; 8(1):3-16. PMID: 7812346.
      View in: PubMed
    183. Roenigk HH, Kuzel T, Rosen S. Interferons for cutaneous T-cell lymphoma monotherapy or combination with PUVA. Australas J Dermatol. 1993; 34(1):13-5. PMID: 8240181.
      View in: PubMed
    184. Kuzel TM, Rosen ST. Radioimmunotherapy of lymphoma. Cancer Treat Res. 1993; 68:1-12. PMID: 8105845.
      View in: PubMed
    185. Dykewicz MS, Rosen ST, O'Connell MM, Patterson R, Kuzel TM, Gilyon KA. Plasma histamine but not anaphylatoxin levels correlate with generalized urticaria from infusions of anti-lymphocyte monoclonal antibodies. J Lab Clin Med. 1992 Aug; 120(2):290-6. PMID: 1500827.
      View in: PubMed
    186. Kuzel TM, Duda RB. The current status of radiolabeled monoclonal antibodies for the diagnosis and treatment of human malignancies. Compr Ther. 1992 Jun; 18(6):16-20. PMID: 1511591.
      View in: PubMed
    187. Kuzel TM, Roenigk HH, Samuelson E, Rosen ST. Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst. 1992 Jan 15; 84(2):119-21. PMID: 1735877.
      View in: PubMed
    188. Kuzel TM, Roenigk HH, Rosen ST. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy. J Clin Oncol. 1991 Jul; 9(7):1298-313. PMID: 2045869.
      View in: PubMed
    189. Gilyon K, Kuzel TM. Cutaneous T-cell lymphoma. Oncol Nurs Forum. 1991 Jul; 18(5):901-8. PMID: 1891419.
      View in: PubMed
    190. Springer EA, Kuzel TM, Rosen ST, Roenigk HH. International symposium on cutaneous T cell lymphoma. Chicago, Illinois, Oct. 19-21, 1989. J Am Acad Dermatol. 1991 Jan; 24(1):136-8. PMID: 1999510.
      View in: PubMed
    191. Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S. PMID: 2258636.
      View in: PubMed
    192. Kuzel TM, Winter JN, Rosen ST, Zimmer AM. Monoclonal antibody therapy of lymphoproliferative disorders. Oncology (Williston Park). 1990 Mar; 4(3):77-84; discussion 84, 89-90, 92-3. PMID: 2144449.
      View in: PubMed
    193. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990 Feb 15; 65(4):885-9. PMID: 2297659.
      View in: PubMed
    194. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA, Evans L, Roenigk HH, Rosen ST. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):203-7. PMID: 2296050.
      View in: PubMed
    195. Kuzel TM, Springer E, Roenigk HH, Rosen ST. Mycosis fungoides: time to define the best therapy. J Natl Cancer Inst. 1990 Feb 07; 82(3):183-5. PMID: 1688623.
      View in: PubMed
    196. Rosen ST, Zimmer AM, Kuzel TM. Monoclonal antibodies in the treatment of non-Hodgkins lymphomas. Cancer Invest. 1990; 8(2):289-90. PMID: 2400951.
      View in: PubMed
    197. Kuzel TM, Benson AB, Gurley AM, Cerullo L. Aggressive intracranial teratocarcinoma with ventriculoperitoneal shunt metastases. Am J Med. 1989 Jun; 86(6 Pt 1):736-8. PMID: 2729335.
      View in: PubMed
    198. Kuzel T, Green D, Stulberg SD, Baron J. Arthropathy and surgery in congenital factor VII deficiency. Am J Med. 1988 Apr; 84(4):771-4. PMID: 3400667.
      View in: PubMed
    Kuzel's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description